91137-53-0

Upstream product

• 92029-40-8 ethyl 2-methyl-5-phenyl-4-oxazolecarboxylate 
• 127916-11-4 ethyl bezoylacetate oxime 
• 106274-54-8 α-acetylamino-β-bromo-cinnamic acid ethyl ester 
• 1198279-56-9 benzyl 2-methyl-5-phenyloxazole-4-carboxylate 

Downstream Products

• 1048340-07-3 2-methyl-5-phenyl-oxazole-4-carbonyl chloride 
• 127916-12-5 1-(2-methyl-5-phenyloxazol-4-yl)ethan-1-one 

Relevant academic research and scientific papers

HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS

The present application relates to certain halo-substituted piperidine compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating substance addiction, panic disorder, anxiety, post-traumatic stress disorder, pain, depression, seasonal affective disorder, an eating disorder, or hypertension.

THIAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS

The invention relates to thiazolidine derivatives of the formula (I) wherein A, B, and R1 are as described in the description, to salts, especially pharmaceutically acceptable salts, of such compounds and to their use as medicaments, especially

THIAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS

The invention relates to thiazolidine derivatives of the formula (I) wherein A, B, and R1 are as described in the description, to salts, especially pharmaceutically acceptable salts, of such compounds and to their use as medicaments, especially

OXAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS

The invention relates to oxazolidine derivatives of the formula (I) wherein A, B, and R1 are as described in the description, to salts, especially pharmaceutically acceptable salts, of such compounds and to their use as medicaments, especially

FLUORINATED AMINOTRIAZOLE DERIVATIVES

The invention relates to fluorinated aminotriazole derivatives of formula (I), wherein A, R1 and R2 are as defined in the description, their preparation and their use as pharmaceutically active compounds.

AMINOTRIAZOLE DERIVATIVES AS ALX AGONISTS

The invention relates to aminotriazole derivatives of formula (I), wherein A, E, R1 and R2 are as defined in the description, their preparation and their use as pharmaceutically active compounds. The compounds are useful for the prevention or treatment of diseases, which respond to the modulation of the ALX receptor such as inflammatory diseases.

Solution versus fluorous versus solid-phase synthesis of 2,5-disubstituted 1,3-azoles. Preliminary antibacterial activity studies

(Chemical Equation Presented) A small library of compounds with an oxa(thia)zole scaffold and structural diversity in both positions 2 and 5 has been synthesized. Double acylation of a protected glycine affords intermediate α-amido-β-ketoesters, which in turn can be dehydrated to afford 1,3-oxazoles or reacted with Lawesson's reagent to furnish 1,3-thiazoles. This procedure was designed with its adaptation to fluorous techniques in mind. Thus, when a protected glycine with a fluorous tag in the ester moiety is used as a starting material, the synthesis can be easily completed without column chromatography purification of intermediate compounds with good to excellent yields, thus affording a suitable entry to the preparation of small libraries of these bioactive compounds. The prepared oxa(thia)zoles were assayed for their antibacterial activity, and several of them were active against Staphylococcus aureus.

Photochemistry of 4-Acylisoxazoles

The photochemistry of 4-acylisoxazoles 4, 5, 13, 14, and 17 was investigated in an effort to clarify literature contradictions and anomalies and to provide a more detailed picture of the nature and number of intermediates involved in photoreactions of these systems.In contrast to a previous report on the photorearrangement of 14, both oxazoles expected from a 2H-azirine intermediate have been observed.Wavelength studies of 5 and the derived 2H-azirine 10 revealed evidence for the involvement of at least two distinct product-forming intermediates.The results of quantum yield and laser photolysis measurements for ketones 4, 14, and 17 have been interpreted in terms of rapid openings of triplet states to form diradical-like intermediates coupled with efficient reclosures (70-99percent).